Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMedTM 670G hybrid closed-loop system in simulated trials compared to NovoLog®. - Benyamin Grosman; Di Wu; Neha Parikh; Anirban Roy; Gayane Voskanyan; Natalie Kurtz; Jeppe Sturis; Ohad Cohen; Magnus Ekelund; Robert A. Vigersky (Comput. Methods Programs Biomed., 2021)